GBDC Stock +24.76% Since The Golden Star Was Identified GBDC Stock +24.76% Since The Golden Star Was Identified Unlock Golden Star List
RSI low/high Values: [ 25 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
AI Analysis of BLCM
Powered by GPT-4
Upgraded!
Stock Analysis
Risk Assessment
Trading Strategy

FAQ

What is the symbol for Bellicum Pharmaceuticals Stock and on which exchange is it traded?
The symbol for Bellicum Pharmaceuticals is BLCM and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell Bellicum Pharmaceuticals Stock?
Bellicum Pharmaceuticals holds several negative signals and this should be a sell candidate, but due to the general chance for a turnaround situation it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.

How to buy Bellicum Pharmaceuticals Stock?
Bellicum Pharmaceuticals Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Bellicum Pharmaceuticals Stock.

What's the current price of Bellicum Pharmaceuticals Stock?
As of the end of day on the 2024-04-19, the price of an Bellicum Pharmaceuticals (BLCM) share was $0.0748.

What is the 52-week high and low for Bellicum Pharmaceuticals Stock?
The 52-week high for Bellicum Pharmaceuticals Stock is $1.31 and the 52-week low is $0.0600.

What is the market capitalization of Bellicum Pharmaceuticals Stock?
As of the 2024-04-19, the market capitalization of Bellicum Pharmaceuticals is 778.326K.

When is the next earnings date for Bellicum Pharmaceuticals?
The upcoming earnings date for Bellicum Pharmaceuticals is May 09, 2024.
Click to get the best stock tips daily for free!

About Bellicum Pharmaceuticals

Bellicum Pharmaceuticals Bellicum Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem ce... BLCM Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT